Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
418.58
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
June 03, 2022
From
United Therapeutics Corporation
Via
Business Wire
Short Volatility Alert: United Therapeutics Corporation
May 26, 2022
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The...
Via
Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
May 24, 2022
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.
Via
Investor's Business Daily
Expert Ratings for United Therapeutics
May 24, 2022
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:
Via
Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
May 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics's Return on Invested Capital Insights
May 18, 2022
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million...
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: United Therapeutics Q1 Earnings
May 04, 2022
United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
May 04, 2022
From
United Therapeutics Corporation
Via
Business Wire
Earnings Scheduled For May 4, 2022
May 04, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Via
Benzinga
Earnings Outlook For United Therapeutics
May 03, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United...
Via
Benzinga
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
April 29, 2022
United Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend United Therapeutics (UTHR) Conference Call Follow this...
Via
Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
April 29, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
April 27, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
April 06, 2022
From
United Therapeutics Corporation
Via
Business Wire
First Human With Pig Heart Transplant Dies: Reuters
March 09, 2022
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical...
Via
Benzinga
10 Biggest Price Target Changes For Monday
February 28, 2022
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading.
Via
Benzinga
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
February 28, 2022
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world
Via
Newswire.com
United Therapeutics Earnings Perspective: Return On Capital Employed
February 25, 2022
Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63%...
Via
Benzinga
FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus
February 24, 2022
United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for additional...
Via
Benzinga
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics's Earnings Outlook
February 23, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
February 21, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
January 21, 2022
From
United Therapeutics Corporation
Via
Business Wire
First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch
January 11, 2022
Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man. What Happened: A Maryland hospital completed the first...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 11, 2022
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
January 06, 2022
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich
Via
InvestorPlace
Mark To Market
January 02, 2022
I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did.
Via
Talk Markets
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today